Recipharm AB - Strategic SWOT Analysis Review

Recipharm AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Recipharm AB (Recipharm) is a pharmaceutical Contract Development and Manufacturing Organisation (CDMO). It provides end-to-end services for the entire product lifecycle, from drug substance development to commercial manufacturing. The company specializes in both small molecules and biologics, offering services in various modalities, including RNA therapies, gene therapy, and biologics manufacturing. Recipharm also provides solutions for solid dosage forms, aseptic fill and finish, and specialized products such as ophthalmics and vaccines. The company operates a global network of facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Feb 05,2025: Recipharm Expands Aseptic Filling Capabilities for Process Development, Pilot Scale and Clinical Supply
Jan 13,2025: ReciBioPharm Secures a Significant Grant to Advance RNA Manufacturing
Nov 19,2024: Recipharm’s full range Oral Solid Dosage (OSD) Capabilities Meet Growing Industry Demands
Oct 03,2024: Recipharm Strengthens Pharmaceutical Development Capabilities with Strategic Investments

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.


Section 1 - About the Company
Recipharm AB - Key Facts
Recipharm AB - Key Employees
Recipharm AB - Key Employee Biographies
Recipharm AB - Major Products and Services
Recipharm AB - History
Recipharm AB - Company Statement
Recipharm AB - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB - Business Description
Recipharm AB - Corporate Strategy
Recipharm AB - SWOT Analysis
SWOT Analysis - Overview
Recipharm AB - Strengths
Recipharm AB - Weaknesses
Recipharm AB - Opportunities
Recipharm AB - Threats
Recipharm AB - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Recipharm AB, Recent Deals Summary
Section 4 – Company’s Recent Developments
Feb 05, 2025: Recipharm Expands Aseptic Filling Capabilities for Process Development, Pilot Scale and Clinical Supply
Jan 13, 2025: ReciBioPharm Secures a Significant Grant to Advance RNA Manufacturing
Nov 19, 2024: Recipharm’s full range Oral Solid Dosage (OSD) Capabilities Meet Growing Industry Demands
Oct 03, 2024: Recipharm Strengthens Pharmaceutical Development Capabilities with Strategic Investments
Oct 01, 2024: Recipharm and Exela Announce Exclusive Strategic Alliance
Sep 16, 2024: Recipharm’s Investment Enhances Efficiency and Speed for Customers and Patients
Sep 04, 2024: Introducing ReciPredict: Revolutionising Drug Product Development and Manufacturing
Mar 26, 2024: Recipharm Attains Major Sustainability Milestones
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Recipharm AB, Recent Deals Summary
List of Figures
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings